First Deals for High-Speed Screening of Ion Channel Drug Targets - WTOC-TV: Savannah, Beaufort, SC, News, Weather & Sports

First Deals for High-Speed Screening of Ion Channel Drug Targets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Biolin Scientific AB

BALLERUP, Denmark, May 14, 2014 /PRNewswire/ --


Sophion Bioscience (sophion.com), part of Biolin Scientific, has received its first purchase orders for its new high throughput screening platform from leading pharma companies. The Sophion Qube™ measures the effect of potential new drug candidates directly on ion channels in living cells. By a unique combination of high quality recordings and high throughput, the Sophion Qube can boost the productivity of the first phases of ion channel drug discovery dramatically.

Qube is a 384-channel automatic patch clamp system that delivers ion channel data at an unprecedented throughput.  At full integration into an existing screening line, Sophion Qube has the capacity to test more than 30,000 compounds in 24 hours. For up to 4 hours unattended operations, Sophion Qube is also available as a stand-alone system.

Sophion Qube is designed to reduce development time of drugs targeting ion channels, for indications like pain, epilepsy, bipolar disorder, depression and cystic fibrosis.

Morten Sunesen, VP of Drug Discovery Systems at Biolin Scientific, commented: "I am very happy to see that the most prestigious ion-channel laboratories in the world have chosen Sophion Qube. It's a solid proof of our concept of uniting manual patch clamp quality with high throughput. Sophion Qube delivers a torrent of information for characterizing ion channels. Instead of screening on secondary information, we're getting direct measurement at the point of action. That's highly valuable for an evidence-based approach in drug discovery, and can greatly enhance the way ion channel drug discovery works".

About Biolin Scientific 

Biolin Scientific is a leading Nordic instrumentation company with revenues of SEK 240 million. Our premium solutions help the pharmaceutical industry to discover new drugs and treatments. Companies working with energy, chemicals and advanced materials use our technologies for material characterization and quality control. Our precision instruments support academic research institutes in their studies of the frontiers of science and technology.

Biolin Scientific proprietary systems are based on nanotechnology and advanced measurement techniques, which have earned leadership in several industries through their commitment to scientific excellence and continuous product development. Our commitment to customer service and application support is a key feature of our operations. We focus on working together with customers and building long-lasting relations. Today, Biolin Scientific provides products and services in more than 70 countries around the world. Our portfolio consists of the following brands: Attension, (attension.com), KSV NIMA (ksvnima.com), Q-Sense (qsense.com) and Sophion (sophion.com).

Contact: Morten Sunesen, VP of global sales and Customer support, +45-40334205


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow